

CAB39 Antibody (N-term) Blocking Peptide
Synthetic peptide
Catalog # BP1650a**Specification**

CAB39 Antibody (N-term) Blocking Peptide - Product InformationPrimary Accession [Q9Y376](#)**CAB39 Antibody (N-term) Blocking Peptide - Additional Information****Gene ID** 51719**Other Names**

Calcium-binding protein 39, MO25alpha, Protein Mo25, CAB39, MO25

Target/Specificity

The synthetic peptide sequence used to generate the antibody [AP1650a](/product/products/AP1650a) was selected from the N-term region of human CAB39. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

CAB39 Antibody (N-term) Blocking Peptide - Protein Information**Name** CAB39**Synonyms** MO25**Function**

Component of a complex that binds and activates STK11/LKB1. In the complex, required to stabilize the interaction between CAB39/MO25 (CAB39/MO25alpha or CAB39L/MO25beta) and STK11/LKB1.

Cellular Location

Cytoplasm.

CAB39 Antibody (N-term) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

CAB39 Antibody (N-term) Blocking Peptide - Images

CAB39 Antibody (N-term) Blocking Peptide - Background

CAB39 together with the STE20-related adaptor-alpha (STRAD alpha) pseudo kinase, forms a regulatory complex capable of stimulating the activity of the LKB1 tumor suppressor protein kinase. The latter is mutated in the inherited Peutz-Jeghers cancer syndrome (PJS). CAB39 binds directly to a conserved Trp-Glu-Phe sequence at the STRAD alpha C terminus, markedly enhancing binding of STRAD alpha to LKB1 and increasing LKB1 catalytic activity. Skeletal muscle contraction results in the phosphorylation and activation of the AMP-activated protein kinase (AMPK) by an upstream kinase (AMPKK). The LKB1-STE-related adaptor (STRAD)-CAB39 complex is the major AMPKK in skeletal muscle; however, LKB1-STRAD-CAB39 activity is not increased by muscle contraction. This relationship suggests that phosphorylation of AMPK by LKB1-STRAD-CAB39 during skeletal muscle contraction may be regulated by allosteric mechanisms.

CAB39 Antibody (N-term) Blocking Peptide - References

Strausberg, R.L., et al., Proc. Natl. Acad. Sci. U.S.A. 99(26):16899-16903 (2002). Lai, C.H., et al., Genome Res. 10(5):703-713 (2000).